Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Invesco Ltd. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Invesco Ltd. trades at $27.87 (market cap $12.77B). The key difference: Invesco Ltd. is far larger — about 4.5× Dyne Therapeutics Inc. Common Stock's market cap, and Invesco Ltd. pays a 2.97% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Invesco Ltd. for 77 Days on average.
| DYN | IVZ | |
|---|---|---|
Market Cap | $2.81B | $12.77B |
Volume | 2,195,902 | 2,758,656 |
Sector | Health | Financials |
52-Week High | $26.78 | $33.31 |
52-Week Low | $14.60 | $22.44 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.13B | $22.93B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Invesco (IVZ) trades at $28.92, down 1.16% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $6.38B in 2025 but negative net margins of -0.93%. Analyst consensus remains cautiously optimistic with a $33.17 price target and no sell ratings, while technical indicators suggest near-term pressure with support at $28.
Investment outlook balances strong asset growth momentum (AUM up 4.7% to $2.56T in August 2026) against profitability challenges. Key opportunities include dividend yield and ETF expansion, while risks center on margin pressure and market volatility. The stock presents value potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
